GB201607393D0 - Biomarkers for early diagnosis of ovarian cancer - Google Patents

Biomarkers for early diagnosis of ovarian cancer

Info

Publication number
GB201607393D0
GB201607393D0 GBGB1607393.4A GB201607393A GB201607393D0 GB 201607393 D0 GB201607393 D0 GB 201607393D0 GB 201607393 A GB201607393 A GB 201607393A GB 201607393 D0 GB201607393 D0 GB 201607393D0
Authority
GB
United Kingdom
Prior art keywords
biomarkers
ovarian cancer
early diagnosis
diagnosis
early
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1607393.4A
Other versions
GB2549763A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GB1607393.4A priority Critical patent/GB2549763A/en
Publication of GB201607393D0 publication Critical patent/GB201607393D0/en
Publication of GB2549763A publication Critical patent/GB2549763A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57449Specifically defined cancers of ovaries
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
GB1607393.4A 2016-04-28 2016-04-28 Biomarkers for early diagnosis of ovarian cancer Withdrawn GB2549763A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1607393.4A GB2549763A (en) 2016-04-28 2016-04-28 Biomarkers for early diagnosis of ovarian cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1607393.4A GB2549763A (en) 2016-04-28 2016-04-28 Biomarkers for early diagnosis of ovarian cancer

Publications (2)

Publication Number Publication Date
GB201607393D0 true GB201607393D0 (en) 2016-06-15
GB2549763A GB2549763A (en) 2017-11-01

Family

ID=56234031

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1607393.4A Withdrawn GB2549763A (en) 2016-04-28 2016-04-28 Biomarkers for early diagnosis of ovarian cancer

Country Status (1)

Country Link
GB (1) GB2549763A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111735949A (en) * 2020-07-17 2020-10-02 北京信诺卫康科技有限公司 Wnt7a and CA125 combined used as early ovarian cancer biomarker and kit
CN111735950A (en) * 2020-07-17 2020-10-02 北京信诺卫康科技有限公司 Combination of FGF18 and CA125 as early ovarian cancer biomarker and kit
CN111912987A (en) * 2020-08-25 2020-11-10 北京信诺卫康科技有限公司 Combination of FGF18 and HE4 as early ovarian cancer biomarker and kit
CN114015689A (en) * 2021-10-26 2022-02-08 江苏大学 shRNA sequence for specifically inhibiting GOS2 gene expression and application thereof
CN116716404A (en) * 2023-06-13 2023-09-08 中国医学科学院北京协和医院 Device for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma based on S100A2
CN116790759A (en) * 2023-08-08 2023-09-22 潍坊医学院 Application of PLEC in early diagnosis and treatment of epithelial ovarian cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102368717B1 (en) * 2018-11-16 2022-02-28 가톨릭대학교 산학협력단 Biomarker for predicting development of hereditary ovarian cancer and use thereof
WO2020101432A1 (en) * 2018-11-16 2020-05-22 가톨릭대학교 산학협력단 Biomarker for predicting onset of hereditary ovarian cancer and use thereof
CN112951325B (en) * 2021-02-18 2023-04-21 北京吉因加医学检验实验室有限公司 Design method of probe combination for cancer detection and application thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111735949A (en) * 2020-07-17 2020-10-02 北京信诺卫康科技有限公司 Wnt7a and CA125 combined used as early ovarian cancer biomarker and kit
CN111735950A (en) * 2020-07-17 2020-10-02 北京信诺卫康科技有限公司 Combination of FGF18 and CA125 as early ovarian cancer biomarker and kit
CN111735950B (en) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 FGF18 and CA125 combined used as early ovarian cancer biomarker and kit
CN111912987A (en) * 2020-08-25 2020-11-10 北京信诺卫康科技有限公司 Combination of FGF18 and HE4 as early ovarian cancer biomarker and kit
CN111912987B (en) * 2020-08-25 2023-07-21 北京信诺卫康科技有限公司 FGF18 and HE4 combined used as early ovarian cancer biomarker and kit
CN114015689A (en) * 2021-10-26 2022-02-08 江苏大学 shRNA sequence for specifically inhibiting GOS2 gene expression and application thereof
CN116716404A (en) * 2023-06-13 2023-09-08 中国医学科学院北京协和医院 Device for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma based on S100A2
CN116716404B (en) * 2023-06-13 2024-01-30 中国医学科学院北京协和医院 Device for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma based on S100A2
CN116790759A (en) * 2023-08-08 2023-09-22 潍坊医学院 Application of PLEC in early diagnosis and treatment of epithelial ovarian cancer
CN116790759B (en) * 2023-08-08 2023-12-01 潍坊医学院 Application of PLEC in early diagnosis and treatment of epithelial ovarian cancer

Also Published As

Publication number Publication date
GB2549763A (en) 2017-11-01

Similar Documents

Publication Publication Date Title
GB201607393D0 (en) Biomarkers for early diagnosis of ovarian cancer
ZA201701753B (en) Biomarkers for assessing breast cancer
SG10202011339RA (en) Microrna biomarker for the diagnosis of gastric cancer
HK1246828A1 (en) Biomarker panel for the detection of cancer
HK1247276A1 (en) Biomarkers for pancreatic cancer
PL3474736T3 (en) Olfactory detector for early diagnosis of ovarian cancer
IL251376A0 (en) Methods for assessing risk of developing breast cancer
IL270717A (en) Biomarkers for diagnosis of lung cancer
HK1248803A1 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
EP3606507A4 (en) Serological biomarkers for early diagnosis of lung cancer
SG10202110526WA (en) Biomarkers for cancer therapeutics
GB201719639D0 (en) Setection of biomarkers
SG10201913528PA (en) Methods of diagnosing cancer
GB201500584D0 (en) Cancer biomarkers
IL266199A (en) Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
SG11201701875YA (en) Methods for detecting ovarian cancer
SG11201701076TA (en) Diagnosis of cancer
GB201619808D0 (en) Biomarkers for the prognosis and diagnosis of cancer
GB201517028D0 (en) Novel biomarkers for pancreatic cancer
HK1249134A1 (en) Biomarkers for colorectal cancer related diseases
EP3189332A4 (en) Biomarkers for detection of breast cancer
HK1250582A1 (en) Pd-ecgf as biomarker of cancer
EP3278111A4 (en) Biomarkers for detection of ovarian cancer
GB201617722D0 (en) Method for determining prognosis of cancer
ITUA20162478A1 (en) NEW DIAGNOSTIC AND PROGNOSTIC MARKERS FOR OVARIAN CANCER

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)